Prediction: Lucid Group Will Soar in 2026. Here's 1 Reason Why.
This could be your opportunity to buy into a high-growth stock at a discount. But if you're really looking for big growth potential, pay attention to Lucid's growth prospects starting in 2026.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Lucid stock is down 17% so far in 2025, and shares are trading at just 7.4 times trailing sales. That's a discount to competitors like Tesla, but a premium to other EV makers like Rivian. Lucid's relative premium to Rivian makes a lot of sense. The recent introduction of Lucid's Gravity SUV platform is expected to help sales nearly double this year. Rivian, meanwhile, isn't expected to release any new models this year.
Thanks to this expected sales growth, Lucid stock trades at just 5 times forward sales. But looking even further ahead, there's reason to believe that Lucid will hit another sales inflection point in 2026 due to one major event.
Last year, it was revealed that Lucid expects to begin production on three new more affordable models, all of which should cost under $50,000. At the time, this timeline seemed aggressive, especially considering its Gravity SUV had yet to be released. Last week, however, Derek Jenkins, a senior vice president at Lucid, confirmed that the company is currently "on track" to begin production of an affordable SUV model in 2026, though he noted that there are "a lot of crazy things going on in the world that can affect that [timeline]."
This new Lucid model is expected to compete with Tesla's existing Model Y and Rivian's anticipated R2 midsize SUV. If the company's timeline remains intact, it could see another huge spike in sales growth next year.
Before you buy stock in Lucid Group, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Lucid Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $594,046!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $680,390!*
Now, it's worth noting Stock Advisor's total average return is 872% — a market-crushing outperformance compared to 160% for the S&P 500. Don't miss out on the latest top 10 list, available when you join .
See the 10 stocks »
*Stock Advisor returns as of April 21, 2025
Ryan Vanzo has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Tesla. The Motley Fool has a disclosure policy.
Prediction: Lucid Group Will Soar in 2026. Here's 1 Reason Why. was originally published by The Motley Fool
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 minutes ago
- Yahoo
Excellent Execution Drove IDEXX Laboratories (IDXX) Shares Amid Macro Challenges
Baron Funds, an investment management company, released its 'Baron Health Care Fund' second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund declined 5.06% (Institutional Shares) in the quarter, against a challenging backdrop for the broader Health Care sector, compared to a 6.19% decline for the Russell 3000 Health Care Index (benchmark) and a 10.99% gain for the Russell 3000 Index (the Index). In addition, please check the fund's top five holdings to know its best picks in 2025. In its second-quarter 2025 investor letter, Baron Health Care Fund highlighted stocks such as IDEXX Laboratories, Inc. (NASDAQ:IDXX). IDEXX Laboratories, Inc. (NASDAQ:IDXX) develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets. The one-month return of IDEXX Laboratories, Inc. (NASDAQ:IDXX) was 4.58%, and its shares gained 22.08% of their value over the last 52 weeks. On July 30, 2025, IDEXX Laboratories, Inc. (NASDAQ:IDXX) stock closed at $572.09 per share, with a market capitalization of $46.009 billion. Baron Health Care Fund stated the following regarding IDEXX Laboratories, Inc. (NASDAQ:IDXX) in its second quarter 2025 investor letter: "Shares of veterinary diagnostics leader IDEXX Laboratories, Inc. (NASDAQ:IDXX) contributed to performance for the quarter after reporting better than-expected financial results. Foot traffic to veterinary clinics in the U.S. remains under pressure, which has continued to hamper aggregate revenue growth. Despite macroeconomic challenges, IDEXX's excellent execution has enabled the company to maintain strong performance. We believe competitive trends are outstanding, and we expect new proprietary innovations and field sales force expansion to be meaningful contributors to growth in 2025. We see increasing evidence that long-term secular trends around pet ownership and pet care spending have structurally accelerated, which should help support IDEXX's long-term growth rate." A veterinarian in a veterinary clinic examining a companion animal. IDEXX Laboratories, Inc. (NASDAQ:IDXX) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 51 hedge fund portfolios held IDEXX Laboratories, Inc. (NASDAQ:IDXX) at the end of the first quarter, which was 58 in the previous quarter. In the first quarter of 2025, IDEXX Laboratories, Inc. (NASDAQ:IDXX) reported organic revenue growth of 5% driven by 4.5% organic revenue gains in the CAG business, 7% organic growth in water, and 4% organic growth in LPD. While we acknowledge the potential of IDEXX Laboratories, Inc. (NASDAQ:IDXX) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered IDEXX Laboratories, Inc. (NASDAQ:IDXX) and shared the list of best stocks to buy according to Brasada Capital Management. In Q2 2025, IDEXX Laboratories, Inc. (NASDAQ:IDXX) contributed to Conestoga Capital Advisors' performance. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 minutes ago
- Yahoo
MSFT: Microsoft Stock Jumps on Q4 Beat, Azure Ignites 39% Surge
July 31 Microsoft (NASDAQ:MSFT) shares surged about 8% in premarket trading Thursday after the tech giant delivered a stronger?than?expected fiscal fourth quarter and offered upbeat guidance, fueled by cloud and AI growth. Warning! GuruFocus has detected 7 Warning Sign with MSFT. Azure revenue rose 39% year over year, topping Wall Street's 34% estimate and surpassing $75 billion on the trailing year, with AI workloads driving incremental demand. Analysts at Wedbush lifted their price target to $625 from $600, citing Microsoft's ability to monetize the AI revolution as enterprises accelerate spending. For fiscal 2026, Microsoft expects Intelligent Cloud revenue between $30.1 billion and $30.4 billion, ahead of the Street's $29.42 billion consensus. Azure growth is projected near 37% in constant currency, with management acknowledging that capacity constraints may persist through the first half of the year. Capital spending is set to exceed $30 billion in the first quarter of fiscal 2026, reflecting an annualized $120 billion run rate to expand data centers and cloud infrastructure. Analysts said the results signal Microsoft is entering a new phase of AI?driven growth, with fiscal 2026 shaping up as an inflection point for its cloud and AI business. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 minutes ago
- Yahoo
What Makes Masimo Corporation (MASI) a Good Investment?
Baron Funds, an investment management company, released its 'Baron Health Care Fund' second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund declined 5.06% (Institutional Shares) in the quarter, against a challenging backdrop for the broader Health Care sector, compared to a 6.19% decline for the Russell 3000 Health Care Index (benchmark) and a 10.99% gain for the Russell 3000 Index (the Index). In addition, please check the fund's top five holdings to know its best picks in 2025. In its second-quarter 2025 investor letter, Baron Health Care Fund highlighted stocks such as Masimo Corporation (NASDAQ:MASI). Incorporated in 1989, Masimo Corporation (NASDAQ:MASI) is a medical technology company that provides various patient monitoring technologies, automation, and connectivity solutions. The one-month return of Masimo Corporation (NASDAQ:MASI) was -6.89%, and its shares gained 45.36% of their value over the last 52 weeks. On July 30, 2025, Masimo Corporation (NASDAQ:MASI) stock closed at $156.02 per share, with a market capitalization of $8.459 billion. Baron Health Care Fund stated the following regarding Masimo Corporation (NASDAQ:MASI) in its second quarter 2025 investor letter: "We added to our position in Masimo Corporation (NASDAQ:MASI), a medical device company that manufactures non-invasive patient monitoring technologies, such as pulse oximetry for measuring blood oxygen levels of patients in the hospital. The company finalized the divestiture of its consumer audio business, which had been a distraction from their core health care business. The company plans to prioritize share repurchases with the proceeds from the sale. The trade war and tariff uncertainty has been an overhang, given Masimo manufactures products in Mexico, Malaysia, and China, but there is reason to be optimistic about de-escalation and trade deals. After meeting with new CEO Katie Szyman, we feel confident in her vision which is focused on achieving commercial excellence, bringing Masimo's AI technology to the hospital, and expanding the company's overall patient monitoring footprint within the hospital. We think the core health care business can continue to grow in the high single digits on the top line, and cost rationalization and disciplined spending should enable the company to more than double EPS within five years." A team of doctors and nurses in the operating room, utilizing a variety of Masimo's medical technology. Masimo Corporation (NASDAQ:MASI) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 37 hedge fund portfolios held Masimo Corporation (NASDAQ:MASI) at the end of the first quarter which was 35 in the previous quarter. While we acknowledge the potential of Masimo Corporation (NASDAQ:MASI) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered Masimo Corporation (NASDAQ:MASI) and shared Baron Health Care Fund's views on the company in the previous quarter. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey.
